日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

除了微卫星检测之外:肿瘤突变负荷评估可以识别出可能对免疫检查点抑制剂有反应的结直肠癌亚群

Fabrizio, David A; George, Thomas J Jr; Dunne, Richard F; Frampton, Garrett; Sun, James; Gowen, Kyle; Kennedy, Mark; Greenbowe, Joel; Schrock, Alexa B; Hezel, Aram F; Ross, Jeffrey S; Stephens, Phillip J; Ali, Siraj M; Miller, Vincent A; Fakih, Marwan; Klempner, Samuel J

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

靶向二代测序鉴定PD-1阻断疗法反应的标志物

Johnson, Douglas B; Frampton, Garrett M; Rioth, Matthew J; Yusko, Erik; Xu, Yaomin; Guo, Xingyi; Ennis, Riley C; Fabrizio, David; Chalmers, Zachary R; Greenbowe, Joel; Ali, Siraj M; Balasubramanian, Sohail; Sun, James X; He, Yuting; Frederick, Dennie T; Puzanov, Igor; Balko, Justin M; Cates, Justin M; Ross, Jeffrey S; Sanders, Catherine; Robins, Harlan; Shyr, Yu; Miller, Vincent A; Stephens, Philip J; Sullivan, Ryan J; Sosman, Jeffrey A; Lovly, Christine M

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative

对肺腺癌患者进行基因组分析,可以揭示治疗靶点,并在标准分子检测结果为阴性时带来临床获益。

Lim, Sun Min; Kim, Eun Young; Kim, Hye Ryun; Ali, Siraj M; Greenbowe, Joel R; Shim, Hyo Sup; Chang, Hyun; Lim, Seungtaek; Paik, Soonmyung; Cho, Byoung Chul

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

广泛的、基于混合捕获的下一代测序技术能够识别出肺腺癌中其他基因组检测方法无法检测到的可操作基因组改变。

Drilon, Alexander; Wang, Lu; Arcila, Maria E; Balasubramanian, Sohail; Greenbowe, Joel R; Ross, Jeffrey S; Stephens, Phil; Lipson, Doron; Miller, Vincent A; Kris, Mark G; Ladanyi, Marc; Rizvi, Naiyer A